中紅醫療(300981.SZ):擬以5000萬元認購產業創新基金份額
格隆匯8月10日丨中紅醫療(300981.SZ)公佈,為高效利用公司自有資金,提升投資水平,優化資金配置,提高盈利能力,拓展在醫療產業領域的競爭力,公司擬以自有資金5000萬元認購共青城祺信股權投資合夥企業(有限合夥)(“產業創新基金”)份額,並簽署《共青城祺信股權投資合夥企業(有限合夥)合夥協議》,基金目標募集規模30億元。
此次投資旨在使公司獲得投資收益的同時,通過基金投向與公司主營業務的協同關係,鏈接公司所在醫療產業領域的優質投資標的,拓展公司潛在多元業務。
Follow us
Find us on
Facebook,
Twitter ,
Instagram, and
YouTube or frequent updates on all things investing.Have a financial topic you would like to discuss? Head over to the
uSMART Community to share your thoughts and insights about the market! Click the picture below to download and explore uSMART app!

Disclaimers
uSmart Securities Limited (“uSmart”) is based on its internal research and public third party information in preparation of this article. Although uSmart uses its best endeavours to ensure the content of this article is accurate, uSmart does not guarantee the accuracy, timeliness or completeness of the information of this article and is not responsible for any views/opinions/comments in this article. Opinions, forecasts and estimations reflect uSmart’s assessment as of the date of this article and are subject to change. uSmart has no obligation to notify you or anyone of any such changes. You must make independent analysis and judgment on any matters involved in this article. uSmart and any directors, officers, employees or agents of uSmart will not be liable for any loss or damage suffered by any person in reliance on any representation or omission in the content of this article. The content of the article is for reference only and does not constitute any offer, solicitation, recommendation, opinion or guarantee of any securities, virtual assets, financial products or instruments. Regulatory authorities may restrict the trading of virtual asset-related ETFs to only investors who meet specified requirements. Any calculations or images in the article are for illustrative purposes only.
Investment involves risks and the value and income from securities may rise or fall. Past performance is not indicative of future performance. Please carefully consider your personal risk tolerance, and consult independent professional advice if necessary.